|Day's Range||48.850 - 49.180|
|52 Week Range||36.810 - 50.240|
|PE Ratio (TTM)||24.75|
|Dividend & Yield||1.58 (3.21%)|
|1y Target Est||N/A|
Total prescriptions of Pfizer's eczema drug Eucrisa have flattened out over recent weeks as Regeneron and Sanofi's Dupixent has picked up steam.
The magnetic tape cartridges in the company's products will be under review.
Sanofi (SNY) reported growth of over 15% at constant exchange rates in its 1Q17 revenues from Genzyme.